Forecast and actual data indicate a steady increase in sales of Genito Urinary System and Sex Hormones in Australia. In 2023, the value stood at USD 12.3 PPP per capita. From 2024 onwards, forecasted values show a consistent upward trend: USD 12.5 in 2024, USD 12.7 in 2025, USD 12.9 in 2026, USD 13.1 in 2027, and USD 13.3 in 2028.
This represents a year-on-year increase of approximately 1.6% each year. Over the last two years, the variation in percentage terms is consistent with the broader five-year Compound Annual Growth Rate (CAGR) of around 1.6%.
Future trends to watch for include:
- Technological advancements in pharmaceutical development
- Changes in government healthcare policies affecting funding and accessibility
- Emerging demographic patterns that may drive demand
- Potential impacts of economic shifts on consumer purchasing power
